$5.62
0.84[17.57%]
Last update: 4:03PM (Delayed 15-Minutes)
Get Real Time Here
Get Real Time Here
$5.62
0[0.00%]
| Open4.770 | Close4.790 |
| Vol / Avg.271.346K / 149.212K | Mkt Cap279.085M |
| Day Range4.470 - 4.820 | 52 Wk Range4.400 - 10.810 |
Monte Rosa Therapeutics Stock (NASDAQ:GLUE), Key Statistics
Monte Rosa Therapeutics Stock (NASDAQ: GLUE) analysis, key statistics.
Valuation Measures
Enterprise Value
81.8M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
1.11
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-53.97%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.3
Tangible Book value per share
4.3
Total Liabilities (Quarterly)
65M
Total Assets
278.6M
Total Liabilities
65M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Monte Rosa Therapeutics Stock (NASDAQ:GLUE), Key Statistics
Monte Rosa Therapeutics Stock (NASDAQ: GLUE) analysis, key statistics.
Valuation Measures
Enterprise Value
81.8M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
1.11
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-53.97%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.3
Tangible Book value per share
4.3
Total Liabilities (Quarterly)
65M
Total Assets
278.6M
Total Liabilities
65M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Monte Rosa Therapeutics Stock (NASDAQ:GLUE), Key Statistics
Monte Rosa Therapeutics Stock (NASDAQ: GLUE) analysis, key statistics.
Valuation Measures
Enterprise Value
81.8M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
1.11
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-53.97%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.3
Tangible Book value per share
4.3
Total Liabilities (Quarterly)
65M
Total Assets
278.6M
Total Liabilities
65M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Monte Rosa Therapeutics Stock (NASDAQ:GLUE), Key Statistics
Monte Rosa Therapeutics Stock (NASDAQ: GLUE) analysis, key statistics.
Valuation Measures
Enterprise Value
81.8M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
1.11
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-53.97%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.3
Tangible Book value per share
4.3
Total Liabilities (Quarterly)
65M
Total Assets
278.6M
Total Liabilities
65M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Monte Rosa Therapeutics Stock (NASDAQ:GLUE), Key Statistics
Monte Rosa Therapeutics Stock (NASDAQ: GLUE) analysis, key statistics.
Valuation Measures
Enterprise Value
81.8M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
1.11
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-53.97%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.3
Tangible Book value per share
4.3
Total Liabilities (Quarterly)
65M
Total Assets
278.6M
Total Liabilities
65M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Monte Rosa Therapeutics Stock (NASDAQ:GLUE), Key Statistics
Monte Rosa Therapeutics Stock (NASDAQ: GLUE) analysis, key statistics.
Valuation Measures
Enterprise Value
81.8M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
1.11
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-53.97%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.3
Tangible Book value per share
4.3
Total Liabilities (Quarterly)
65M
Total Assets
278.6M
Total Liabilities
65M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Monte Rosa Therapeutics Stock (NASDAQ:GLUE), Key Statistics
Monte Rosa Therapeutics Stock (NASDAQ: GLUE) analysis, key statistics.
Valuation Measures
Enterprise Value
81.8M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
1.11
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-53.97%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.3
Tangible Book value per share
4.3
Total Liabilities (Quarterly)
65M
Total Assets
278.6M
Total Liabilities
65M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Monte Rosa Therapeutics Stock (NASDAQ:GLUE), Key Statistics
Monte Rosa Therapeutics Stock (NASDAQ: GLUE) analysis, key statistics.
Valuation Measures
Enterprise Value
81.8M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
1.11
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-53.97%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.3
Tangible Book value per share
4.3
Total Liabilities (Quarterly)
65M
Total Assets
278.6M
Total Liabilities
65M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Monte Rosa Therapeutics Stock (NASDAQ:GLUE), Key Statistics
Monte Rosa Therapeutics Stock (NASDAQ: GLUE) analysis, key statistics.
Valuation Measures
Enterprise Value
81.8M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
1.11
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-53.97%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.3
Tangible Book value per share
4.3
Total Liabilities (Quarterly)
65M
Total Assets
278.6M
Total Liabilities
65M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -